Compare Amicus Therapeutics vs Motif BioSciences
Customers evaluate the quality of Amicus Therapeutics's products using the following success metrics.
Overview
Amicus Therapeutics is 22 yrs old and is based in United States.
Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company. It develops therapies to treat a range of rare metabolic diseases. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Motif BioSciences is based in United Kingdom
Motif BioSciences is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Motif has a lead antibiotic candidate, iclaprim, and MTF-001, a preclinical program to design a best-in-class dihydrofolate reductase inhibitor (DHFRi). Discussions and negotiations with academic institutes are under way to build a portfolio of antibiotic candidates through licensing. It is anticipated that Motif's lead antibiotic candidate could be ready for commercialization as early as 2018.
Demo Video
Leadership
John F Crowley (Chief Executive Officer, President)
Stephen Cass (Chief Executive Officer, President)
Investors
Novo Ventures, New Enterprise Associates
Amphion Innovations PLC. and Acceleration International
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Amicus Therapeutics has not claimed their profile.
Work for Amicus Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Amicus Therapeutics?
Claim your profile now.
Information not available because Motif BioSciences has not claimed their profile.
Work for Motif BioSciences? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Motif BioSciences?
Claim your profile now.